Ask AI
ProCE Banner Activity

Breast Cancer Highlights From ASCO 2026: Expert Perspectives on Emerging Data

Clinical Thought

In this activity, experts review key breast cancer findings presented at ASCO 2026, including phase III data on genomic-guided chemotherapy de-escalation in HR+/HER2- early disease, biomarker analyses of adjuvant CDK4/6 inhibition, ctDNA-guided treatment switching for emergent ESR1 mutations, and first-line TROP-2 antibody–drug conjugates in metastatic TNBC. Faculty also summarize early-phase studies targeting endocrine and PI3K/AKT pathway resistance and how trial design, biomarker context, follow-up maturity, regulatory status, and toxicity should shape interpretation of these data and their application to treatment selection, sequencing, and patient counseling.

Released: August 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from breast cancer studies at ASCO 2026 and expert guidance to optimize personalized breast cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with breast cancer most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for breast cancer to accelerate their effective incorporation into clinical practice

Financial Disclosures

Primary Author

Nerea Lopetegui-Lia, MD: advisor: Daiichi Sankyo, Pfizer.

Hope S. Rugo, MD, FASCO: consultant/advisor/speaker: BioNTech, Bristol Myers Squibb, Helsinn, Napo; researcher (paid to institution): ALX Oncology, Ambryx, AstraZeneca, Bicycle, Daiichi Sankyo, F. Hoffmann-La Roche/Genentech, Gilead Sciences, Lilly, Mabwell, Merck, Novartis, Pfizer, PhoenixMD, Relay, Stemline.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.